KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?

Thomas McLaughlin, Marcelo Febo, Thomas Simpatico, Rajendra D. Badgaiyan, Debmalya Barh, Kristina Dushaj, Eric R. Braverman, Mona Li, Margaret A. Madigan and Kenneth Blum

 

Abstract

Major Depressive Disorder (MDD) is a condition that affects approximately 12% of the population [1] and recurs at a rate between 50-85% regardless of treatment [2]. Treatment resistant depression (TRD) is considered if patients
do not show alleviation of depressive symptoms after at least two trials of antidepressants from different pharmacologic classes [3]. Current antidepressant therapies which modulate serotonin, norepinephrine, and dopamine are based on the monoamine hypothesis, but the mechanism of MDD is now known to be more complex [4]. More aggressive treatment options including ketamine infusions, deep brain stimulation, and magnetic seizure therapy [5, 6] have also been applied in attempts to influence the unknown areas of our understanding of depression.

Published on: May 19, 2016
doi: 10.17756/jrdsas.2016-022
Citation: McLaughlin T, Febo M, Simpatico T, Badgaiyan RD, Barh D, et al. 2016. KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?J Reward Defic Syndr Addict Sci 2(1): 3-13.
 
222
Downloads